| Quarterly Financials | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 1,764 | 2,200 | 2,457 | 2,130 | 2,103 | 2,642 | 2,772 | 2,682 | 2,517 | 2,976 | 3,173 | 3,286 | 3,333 | 3,653 | 3,791 |
| Expenses | 1,441 | 1,724 | 1,835 | 1,654 | 1,636 | 1,924 | 2,025 | 2,000 | 1,836 | 2,196 | 2,217 | 2,383 | 2,401 | 2,724 | 2,776 |
| EBITDA | 323 | 476 | 622 | 477 | 467 | 718 | 746 | 681 | 681 | 780 | 956 | 903 | 933 | 930 | 1,016 |
| Operating Profit % | 17 % | 21 % | 24 % | 21 % | 20 % | 25 % | 25 % | 23 % | 24 % | 23 % | 28 % | 26 % | 22 % | 24 % | 25 % |
| Depreciation | 47 | 78 | 79 | 85 | 85 | 87 | 97 | 110 | 100 | 103 | 101 | 187 | 231 | 219 | 222 |
| Interest | 13 | 16 | 10 | 13 | 5 | 6 | 9 | 9 | 9 | 11 | 7 | 221 | 191 | 171 | 170 |
| Profit Before Tax | 263 | 382 | 533 | 379 | 377 | 625 | 641 | 562 | 572 | 666 | 849 | 495 | 511 | 541 | 624 |
| Tax | 70 | 84 | 110 | 83 | 84 | 130 | 130 | 103 | 95 | 123 | 190 | 111 | 86 | 96 | 104 |
| Net Profit | 193 | 298 | 423 | 296 | 294 | 494 | 511 | 460 | 477 | 543 | 659 | 385 | 425 | 445 | 520 |
| EPS in ₹ | 4.74 | 7.30 | 10.48 | 7.09 | 7.13 | 12.15 | 12.51 | 11.33 | 11.76 | 13.39 | 16.31 | 9.46 | 10.19 | 10.62 | 12.39 |
Mankind Pharma
Mankind Pharma
2,205.50
-0.80
(-0.04%)
Market Cap
₹91,033.90 Cr
PE Ratio
52.05
Volume
2,99,678.00
Day High - Low
₹2,215.70 - ₹2,191.60
52W High-Low
₹3,054.80 - ₹2,115.10
Key Fundamentals
Market Cap
91,033.90 Cr
EPS
49.28
PB Ratio
6.04
Book Value
370.34
EBITDA
3,554.70
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals ROE Growth %
-
Debt to Equity
0.37
Analyst Rating and Forecast
- By Refinitiv from16 analysts
Actual
Company News
View All News
SES ESG Research Private Limited independently assigned an Environmental, Social, and Governance (ESG) rating of 64.8 (Grade B) to Mankind Pharma for FY2024-25 based on publicly available information. The company disclosed this rating to stock exchanges as required under SEBI listing regulations, noting they did not engage SES for this assessment.
Mankind Pharma Allots 46,582 Equity Shares Under Employee Stock Option Plan10 days ago
Mankind Pharma allotted 46,582 equity shares with face value of ₹1 each to eligible employees who exercised their options under the ESOP Plan 2022 at an exercise price of ₹860 per share. The allotment increased the company's paid-up share capital from 41,27,58,490 equity shares to 41,28,05,072 equity shares, with the new shares ranking pari-passu with existing equity shares.
Mankind Pharma Sees Rs. 70.02 Crore Block Trade on NSENov 21, 2025
Mankind Pharma witnessed a block trade worth Rs. 70.02 crores involving 314,302 shares executed at Rs. 2,227.90 per share on NSE. The transaction represents a significant institutional trading activity in the pharmaceutical company's stock.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,805.30 | #1 4,33,151.90 | 40.68 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 63.65 | |
6,473.50 | 1,71,851.10 | 69.05 | 9,712.00 | 18.67 | 2,191 | 35.10 | 50.10 | |
3,785.90 | 1,28,132.10 | 58.80 | 11,539.40 | 6.99 | 1,911 | 30.46 | 60.01 | |
1,520.80 | 1,22,843.20 | 22.73 | 28,409.50 | 7.12 | 5,291 | 3.71 | 48.01 | |
1,275.20 | 1,06,429.90 | #1 18.15 | 33,741.20 | 16.73 | 5,725 | -0.38 | 61.42 | |
2,098.80 | 95,863.60 | 21.34 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 67.65 | |
931.45 | 93,725.70 | 18.56 | 23,511.00 | 18.55 | 4,615 | 34.60 | 40.18 | |
2,205.50 | #8 91,033.90 | #8 52.05 | #8 12,744.20 | #1 20.90 | #9 2,007 | #10 -21.05 | 32.30 | |
1,217.60 | 70,718.40 | 20.70 | 32,345.60 | 9.43 | 3,484 | 3.81 | 58.88 | |
5,675.50 | 67,859.10 | 28.29 | 13,458.30 | 3.70 | 2,216 | 10.98 | 53.12 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
20.90 %
Net Income Growth
3.39 %
Cash Flow Change
12.12 %
ROE
-32.07 %
ROCE
-46.01 %
EBITDA Margin (Avg.)
5.21 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 6,373 | 9,148 | 9,715 | 11,963 | 27,760 |
| Fixed Assets | 1,664 | 3,588 | 4,251 | 4,545 | 19,005 |
| Current Assets | 3,907 | 4,407 | 4,328 | 6,568 | 6,988 |
| Capital Work in Progress | 372 | 702 | 550 | 282 | 826 |
| Investments | 1,512 | 1,110 | 1,346 | 2,568 | 2,042 |
| Other Assets | 2,824 | 3,749 | 3,568 | 4,568 | 5,887 |
| Total Liabilities | 6,373 | 9,148 | 9,715 | 11,963 | 27,760 |
| Current Liabilities | 1,353 | 2,624 | 1,863 | 2,120 | 5,664 |
| Non Current Liabilities | 156 | 208 | 229 | 268 | 7,528 |
| Total Equity | 4,863 | 6,316 | 7,623 | 9,576 | 14,568 |
| Reserve & Surplus | 4,682 | 6,115 | 7,395 | 9,323 | 14,291 |
| Share Capital | 40 | 40 | 40 | 40 | 41 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 103 | -92 | 156 | 22 | 77 | 22 |
| Investing Activities | -436 | -1,222 | -1,369 | -1,052 | -2,081 | -12,624 |
| Operating Activities | 1,070 | 1,137 | 920 | 1,813 | 2,152 | 2,413 |
| Financing Activities | -531 | -8 | 605 | -740 | 5 | 10,233 |
Share Holding
| % Holding | Sept 2022 | Mar 2023 | May 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 79.00 % | 76.50 % | 76.50 % | 76.50 % | 76.50 % | 76.50 % | 74.88 % | 74.87 % | 74.87 % | 72.71 % | 72.70 % | 72.68 % | 72.67 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 9.87 % | 11.58 % | 12.37 % | 13.34 % | 12.92 % | 13.07 % | 12.84 % |
| DIIs | 0.00 % | 2.64 % | 2.64 % | 4.64 % | 4.39 % | 9.49 % | 11.14 % | 9.95 % | 9.90 % | 11.06 % | 11.48 % | 11.50 % | 11.92 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 4.15 % | 4.15 % | 1.02 % | 1.11 % | 1.14 % | 1.22 % | 1.46 % | 1.55 % | 1.60 % | 1.64 % | 1.52 % | 1.36 % |
| Others | 21.00 % | 16.71 % | 16.71 % | 17.83 % | 18.00 % | 12.87 % | 2.89 % | 2.15 % | 1.31 % | 1.30 % | 1.26 % | 1.23 % | 1.21 % |
| No of Share Holders | 17 | 4,02,322 | 4,02,322 | 1,31,918 | 1,34,731 | 1,27,449 | 1,35,116 | 1,53,450 | 1,63,854 | 1,72,431 | 1,80,597 | 1,79,549 | 1,70,347 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 09 Aug 2024 |  Annual General Meeting | NA | 09 Aug 2024 | 2,114.50 | 2,068.60 |
| 05 Nov 2024 |  Quarterly Result Announcement | NA | 05 Nov 2024 | 2,506.95 | 2,734.95 |
| 23 Jan 2025 | Quarterly Result Announcement | NA | 23 Jan 2025 | 2,738.25 | 2,515.05 |
| 21 May 2025 | Quarterly Result Announcement | NA | 21 May 2025 | 2,430.05 | 2,550.70 |
| 31 Jul 2025 | Quarterly Result Announcement | NA | 31 Jul 2025 | 2,578.00 | 2,575.00 |
| 07 Aug 2025 | Annual General Meeting | NA | 07 Aug 2025 | 2,386.35 | 2,553.25 |
| 08 Aug 2025 |  Dividend | ₹ 1.00 /share | 08 Aug 2025 | 2,575.00 | 2,541.90 |
| 06 Nov 2025 | Quarterly Result Announcement | NA | 06 Nov 2025 | 2,431.65 | 2,369.35 |
Announcements
Intimation Regarding ESG Rating
8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Allotment10 days ago
10 days agoIntimation Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015Nov 16, 2025
Nov 16, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Nov 15, 2025
Nov 15, 2025Announcement under Regulation 30 (LODR)-Credit RatingNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 07, 2025
Nov 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 07, 2025
Nov 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 06, 2025
Nov 06, 2025Financial Results For The Quarter And Half Year Ended 30Th September 2025Nov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 06, 2025
Nov 06, 2025Board Meeting Outcome for Outcome Of Board MeetingNov 06, 2025
Nov 06, 2025Intimation Regarding ESG RatingNov 04, 2025
Nov 04, 2025Intimation Regarding ESG RatingOct 29, 2025
Oct 29, 2025Announcement under Regulation 30 (LODR)-Credit RatingOct 29, 2025
Oct 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 29, 2025
Oct 29, 2025Board Meeting Intimation for Approval Of Financial Results For The Quarter And Half Year Ended On September 30 2025Oct 27, 2025
Oct 27, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionOct 10, 2025
Oct 10, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 04, 2025
Oct 04, 2025Closure of Trading WindowSep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 15, 2025
Sep 15, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 10, 2025
Sep 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 09, 2025
Sep 09, 2025Intimation Of Receipt Of Approval For ReclassificationSep 02, 2025
Sep 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 27, 2025
Aug 27, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 25, 2025
Aug 25, 2025Intimation Regarding ESG RatingAug 22, 2025
Aug 22, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionAug 19, 2025
Aug 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 08, 2025
Aug 08, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 08, 2025
Aug 08, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 06, 2025
Aug 06, 2025Intimation For Submission Of Application For ReclassificationAug 03, 2025
Aug 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 01, 2025
Aug 01, 2025Announcement Under Regulation 30- TDS Communication To The Shareholders.Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-RestructuringJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-AcquisitionJul 31, 2025
Jul 31, 2025Intimation Of Record DateJul 31, 2025
Jul 31, 2025Corporate Action-Board approves DividendJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJul 31, 2025
Jul 31, 2025Un-Audited Financial Results For The Quarter Ended On June 30 2025Jul 31, 2025
Jul 31, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On July 31 2025Jul 31, 2025
Jul 31, 2025Mutual Fund Holdings
SBI Large Cap Direct Plan-Growth 
HDFC Large Cap Fund Direct-Growth 
Axis ELSS Tax Saver Direct Plan-Growth 
Aditya Birla Sun Life Flexi Cap Fund Direct-Growth 
Invesco India Contra Fund Direct-Growth 
PGIM India Midcap Fund Direct-Growth 
Canara Robeco Large Cap Fund Direct-Growth 
Kotak Small Cap Fund Direct-Growth 
Nippon India Pharma Fund Direct-Growth 
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth 
Edelweiss Mid Cap Direct Plan-Growth 
Sundaram Mid Cap Fund Direct-Growth 
Bandhan Large & Mid Cap Fund Direct-Growth 
Franklin India Opportunities Direct Fund-Growth Technical Indicators
RSI(14)
Neutral 32.30
ATR(14)
Less Volatile 40.74
STOCH(9,6)
Neutral 24.85
STOCH RSI(14)
Neutral 29.40
MACD(12,26)
Bullish 4.08
ADX(14)
Weak Trend 24.23
UO(9)
Bearish 44.19
ROC(12)
Downtrend And Accelerating -0.79
WillR(14)
Neutral -77.53
About Mankind Pharma
Mankind Pharma Limited is an Indian pharmaceutical company incorporated in 1991. It develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. The company operates in various therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. Mankind Pharma entered the consumer healthcare segment in 2007 and has since expanded into animal healthcare, female infertility treatments, and oncology. The company operates 23 manufacturing facilities across India with a total installed capacity of 40.77 billion units as of March 31, 2022. In April 2023, Mankind Pharma went public through an Initial Public Offer. The company has acquired several subsidiaries and brands, and has expanded internationally with subsidiaries in the US, Singapore, Nepal, and UAE.
Listing Date
09 May, 2023(2 Years,
-2 days)
Chairperson NameRAMESH CHAND JUNEJA
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
